Information in this document marked with “^^” has been omitted and filed separately with the U.S. Securities and Exchange
Commission pursuant to a request for confidential treatment.
STRATEGIC MARKETING & COOPERATION AGREEMENT
This Strategic Marketing & Cooperation Agreement (hereby: “Marketing Agreement”) is entered into on 23 April 2010 by and
between, Nilimedix Ltd., based in 3 HaSadna Street. TIRAT HaKARMEL, ISRAEL (Including Medx-set Ltd), (hereinafter:
“Nilimedix” or “Company”); and China National Pharmaceutical Foreign Trade Corp. (Sinopharm) of No 20 Zhichun Road,
Haidian District, Beijing, China (hereinafter: Sinopharm “Sinopharm”)
(for the purpose of this Agreement each of Nilimedix and Sinopharm may sometimes be referred to as a “Party” and collectively
Whereas parties agreed to cooperate in commercializing Company’s products in China (the “Territory”) and in the strategic
forming and execution of a marketing plan to roll out a marketing and operations campaign supporting the distribution activities
described in this Agreement.
Whereas, in light of their mutual understandings the Parties herewith wish to set forth their mutual relationship in writing under
NOW THEREFORE THE PARTIES HAVE AGREED AS FOLLOWS:
1.1 The term of this Agreement shall be exactly as that of the Distribution Agreement signed between the parties. All
other terms and general stipulations relating to the Distribution Agreement will relate to this agreement as well.
2. Operations and Expenses .
2.1 The detailed operations of Sinopharm under this Agreement are subject to the sole control and management of
Sinopharm. Sinopharm shall be responsible for all of its own employees and expenses, including, without limitation,
postage, cable expenses, shipping, insurance, financing, costs and taxes of complying with the exportation or
importation of the Products. Sinopharm shall provide, at its own expense, such office space and fac